Despite a false start back in the 1980s, biotech today really does appear to be the dominant driver in drug discovery and manufacture. A culmination of biotech-based innovations has led to real progress in potential treatments for some of the most difficult diseases, fundamentally changing the basic approach to health and medicine.
Biotech is transforming the pharmaceutical industry, whether through the use of enzymes and ‘greener’ chemistry, or through cell culture and the design and production of biologicals and regenerative therapies. Despite the challenges, more and more companies are investing in biopharmaceutical facilities and those supplying the market with biopharmaceutical production components, analytics, quality control or formulation services are seeing growing demand for business.
Biotechnology has not only increased our knowledge of how human cells form and function, but also how enzymes, cell cultures, plants, bacteria and viruses can be used to produce active pharmaceutical ingredients in a more economic fashion.
Not yet a Subscriber?
This is a small extract of the full article which is available ONLY to premium content subscribers. Click below to get premium content on Manufacturing Chemist.
Subscribe now Already a subscriber? Sign in here.Featured companies
- Companies:
- Pfizer
- Biocitech
- WuXi AppTec (Shanghai) Co
- Cellectis
- Green Cross Corp
- Merck Electronics KGaA
- Immune Pharmaceuticals
- Ambrx
- Intrexon